Pediatric hepatitis C

Pediatric Subcommittee of FDA's Anti-Infective Drugs Advisory Committee will discuss drug development for pediatric patients with chronic hepatitis C on April 23. FDA will also present an update on efforts to ensure adequate labeling and proper pediatric use of therapies during the meeting. On April 24, the committee will discuss clinical trial design for antimuscarinics to control drooling in children with cerebral palsy and other neurological diseases as well as ethical issues for performing studies in children with special needs. The meeting will begin at 8 a.m. both days at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md